Genetic Analysis AS and Thalys Medical Technology Group are pleased to announce the launch of a microbiome test to the Chinese Consumer Health market
OSLO, NORWAY/SHANGHAI, CHINA – 22. April 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces the launch of a microbiome test for the…
Genetic Analysis AS publishes year-end report 2024
OSLO, NORWAY – 26 February 2025: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the year-end report for the period 1 January – December 31, 2024. The year-end report…
Genetic Analysis and Ferring Pharmaceuticals Announce A Collaboration To Develop A New Microbiome Rapid Diagnostic Test
Oslo, Norway – 20 December, 2024 – Ferring Pharmaceuticals and microbiome diagnostics specialists Genetic Analysis will bring together two established technologies – Genetic Analysis’ PCR-based microbiome diagnostics platform (GA-map®1) and…
Genetic Analysis AS: Mandatory notification of trade – Primary Insiders
OSLO, NORWAY – 25 November 2024: Genetic Analysis AS (“GA” or “the Company”) announces that members of the management has bought GEAN-shares. Ronny Hermansen, CEO of Genetic Analysis AS, has…
Publication of Q3 Interim Report January – September 2024
OSLO, NORWAY – 15 November 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the third quarter and the first nine months of 2024. The interim…
Publication of Half-year report 2024
OSLO, NORWAY – 30 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for H1, and april – June 2024. The Half-year…
Genetic Analysis AS launches the GA-map® Discovery reagent kit – a precision microbiome research assay
OSLO, NORWAY – 15 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the launch of a microbiome research product for Luminex xMAP® users globally. The…
Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology
OSLO, NORWAY – August 8, 2024: Microbiome DX company Genetic Analysis AS (“GA”) announces the completion and launch of a consumer microbiome testing platform in partnership with Prokarimi AS (“Prokarimi”)….
Minutes from the Extraordinary General Meeting 17 July 2024 in Genetic Analysis AS
Oslo, Norway, July 17, 2024 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held an Extraordinary General Meeting today, July 17th, at 09:00 hours (CET) on the Company’s premises in…
Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
OSLO, NORWAY – July 15, 2024: Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) hereby announces that the direct issue which was announced in a press release on…
Genetic Analysis AS: Mandatory notification of trade – Primary Insider
OSLO, NORWAY – 04 July 2024: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares. Ronny Hermansen, CEO of Genetic Analysis AS,…
Notice of Extraordinary General Meeting 2024
Oslo, Norway, July 3, 2024 – Notice is hereby served that an extraordinary general meeting of Genetic Analysis AS (the “Company”) will be held on Wednesday 17 July 2024 at…
Genetic Analysis: Flagging notification
OSLO, NORWAY – July 1, 2024: Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) hereby announces that an existing shareholder, Muen Invest AS, crosses the flagging threshold as…
Genetic Analysis announces placement of a directed share issue of approximately NOK 4.97 million
Genetic Analysis AS (“GA” or the “Company”) is pleased to announce that it has successfully placed a directed issue and on basis of commitments received from current major shareholders, the…
Genetic Analysis: Awarded important EU patent covering a companion diagnostic method for optimising IBS interventions
OSLO, NORWAY – 13 June 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today the grant of an important patent (EP3526340) by the European Patent Office…